In a significant milestone for medical imaging, Bracco Imaging and Avicenna.AI have announced that they have secured US Food and Drug Administration (FDA) clearance for their jointly developed artificial intelligence (AI) solution designed to detect and characterize brain aneurysms. This regulatory achievement marks the first successful collaborative outcome for the two companies since they entered into a strategic partnership in March 2026, signaling a robust shift toward AI-integrated clinical workflows.
The new tool, branded as UPTUNITY | Aneurysm, is poised to become a foundational component of Bracco’s newly launched UPTUNITY portfolio. By leveraging advanced algorithmic analysis of computed tomography angiography (CTA) images, the platform aims to provide radiologists with precise, actionable insights, potentially reducing the cognitive burden on clinicians while improving the accuracy of life-saving interventions.
The Core Technology: How UPTUNITY | Aneurysm Works
At its core, UPTUNITY | Aneurysm is designed to serve as an intelligent diagnostic assistant. The software utilizes sophisticated deep-learning models to analyze CTA images of cerebral arteries, specifically trained to identify saccular brain aneurysms that measure 3mm or greater.
Diagnostic Capabilities
The primary function of the tool is the rapid detection of suspicious lesions. Upon identifying a potential aneurysm, the software generates detailed data regarding its precise anatomical location and volumetric size. This information is then synthesized for the radiologist, who remains the final authority in the diagnostic process.
Longitudinal Monitoring
Beyond initial discovery, the platform addresses a critical clinical challenge: the longitudinal follow-up of unruptured aneurysms. For patients living with a diagnosed aneurysm, the tool includes a specialized module for quantitative measurement. This functionality allows physicians to perform a direct comparison between historical examinations and current scans. By tracking minute changes in size and morphology over time, the tool provides a standardized, objective baseline, which is essential for determining the timing of surgical or endovascular interventions.
Chronology of Development: A Strategic Partnership
The path to FDA clearance for UPTUNITY | Aneurysm reflects a disciplined, fast-tracked development cycle that highlights the synergy between legacy diagnostic giants and agile AI innovators.
- March 2026: Bracco Imaging and Avicenna.AI formally announce a strategic partnership. The collaboration was established with the goal of integrating Avicenna’s AI-powered diagnostic software into Bracco’s global clinical network.
- Spring–Summer 2026: The teams focus on rigorous technical validation and clinical trial data collection to ensure the tool meets the stringent accuracy standards required by the FDA.
- Late 2026: Submission of the technical file to the FDA, demonstrating the efficacy of the tool in identifying aneurysms in diverse patient populations.
- November 2026: Official FDA clearance is granted, making UPTUNITY | Aneurysm the inaugural product under the UPTUNITY umbrella.
- November 29 – December 3, 2026: The product makes its public debut at the Radiological Society of North America (RSNA) Annual Meeting in Chicago, the premier global event for the medical imaging community.
Supporting Data and Market Context
The integration of AI into radiology is not merely a technological trend; it is an industrial necessity driven by increasing patient volumes and the complexity of modern diagnostic requirements.
The Rise of Interpretive AI
Bracco characterizes the UPTUNITY portfolio as an expansion into "interpretive AI." Unlike traditional image-processing software that merely enhances clarity, interpretive AI actively analyzes the pixels to suggest clinical findings. This aligns with a broader industry trend where software acts as a "second pair of eyes" to mitigate the risks of human error—such as fatigue or oversight—inherent in the analysis of hundreds of complex scans per day.
Market Projections
According to analysis by GlobalData, the broader healthcare AI market is experiencing an unprecedented growth trajectory. With a compound annual growth rate (CAGR) of approximately 37%, the sector is projected to reach a valuation of $57.4 billion by 2029. Radiology remains the primary domain for these investments; the vast majority of AI-enabled medical devices approved by the FDA in 2026 were indicated for diagnostic imaging functions, illustrating a clear regulatory and commercial prioritization of this technology.
Official Responses and Strategic Vision
The collaboration between Bracco and Avicenna.AI is built on the premise that hardware and software are no longer siloed entities.
Bridging the Gap
Fabio Tedoldi, Head of Global Research and Development at Bracco, emphasized the patient-centric nature of the innovation. "For a patient with an unruptured aneurysm, the follow-up scan always brings the same question: has it changed?" Tedoldi noted. "UPTUNITY | Aneurysm supports physicians from first detection through subsequent monitoring, with comparable readings at every exam. This continuity of care is where we believe digital health adds the most value."
The "See and Act" Philosophy
Cyril Di Grandi, CEO of Avicenna.AI, reflected on the synergy between the two companies. "Bracco has spent decades lighting up the vessels [through contrast agents and imaging technology]. But an image only helps if what it shows is seen," said Di Grandi. "Avicenna.AI brings AI assistance to those images, helping radiologists detect an aneurysm greater than 3mm and track how it changes over time. UPTUNITY | Aneurysm combines these two strengths, turning a head CTA into a story the radiologist can follow."
Clinical and Economic Implications
The deployment of UPTUNITY | Aneurysm carries significant weight for healthcare systems and patient outcomes.
Clinical Workflow Efficiency
By automating the screening process for aneurysms, the tool allows radiologists to prioritize urgent cases. In an emergency room setting, where time-to-treatment is a critical factor for patient survival, AI-driven triage can significantly shorten the interval between image acquisition and definitive diagnosis.
Enhancing Patient Safety
The ability to standardize follow-up measurements is a major improvement over manual measurement techniques, which can be subject to inter-observer variability. By providing consistent, AI-calculated metrics, the software helps ensure that clinicians are making decisions based on accurate data, reducing the likelihood of unnecessary interventions or, conversely, the failure to identify a growing aneurysm that requires urgent surgery.
Expanding the Digital Health Ecosystem
For Bracco, UPTUNITY | Aneurysm is a strategic anchor. It complements existing digital assets such as AiMIFY, a tool for contrast enhancement in brain MRI developed in partnership with Subtle Medical. By building a portfolio of interoperable AI solutions, Bracco is positioning itself not just as a provider of imaging agents, but as an end-to-end partner in the digital transformation of radiology departments worldwide.
Future Outlook: Commercialization and Beyond
As the industry converges on Chicago for the RSNA 2026 meeting, the spotlight is firmly on the rollout of this technology. With FDA clearance secured, the companies have shifted their focus to commercialization. Avicenna.AI is slated to spearhead the promotion and distribution of the UPTUNITY | Aneurysm tool, leveraging its specialized expertise in AI software delivery to ensure rapid adoption in hospitals and imaging centers across the United States.
Looking ahead, the success of UPTUNITY | Aneurysm will likely serve as a litmus test for the future of collaborative med-tech development. As healthcare systems look to combat rising costs and clinician burnout, the demand for "intelligent" imaging solutions that offer tangible clinical benefits will only accelerate. Bracco and Avicenna.AI have established a model that, if successful, may define the standard for how medical imaging companies integrate artificial intelligence into the standard of care for the next decade.
In summary, the introduction of UPTUNITY | Aneurysm represents a maturation of the AI market. It moves beyond the experimental phase and into a period of deep, vertical integration, where AI is embedded directly into the tools that clinicians use every day, ultimately creating a safer, more efficient, and more precise diagnostic landscape.
About the Author
